



Clinical trial results:

PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2009-012769-74
Trial protocol	FI
Global end of trial date	23 October 2012

Results information

Result version number	v2 (current)
This version publication date	23 March 2016
First version publication date	01 August 2015
Version creation reason	<ul style="list-style-type: none">• New data added to full data set• Correction of full data set reporting periods and duplicate AEs in their data

Trial information

Trial identification

Sponsor protocol code	A4021040
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00976508
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 East 42nd Street, New York, United States, 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 July 2013
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	23 October 2012
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and tolerability of figitumumab plus pegvisomant in subjects with advanced solid tumors.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 November 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 4
Country: Number of subjects enrolled	Germany: 5
Country: Number of subjects enrolled	United States: 11
Country: Number of subjects enrolled	Canada: 3
Worldwide total number of subjects	23
EEA total number of subjects	9

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	20
From 65 to 84 years	3

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study was started on 11-November-2009 and ended on 23 October 2012 in Finland, Germany, United States and Canada.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Figitumumab 20mg/kg + Pegvisomant 10 mg

Arm description:

Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days. 18 subjects were enrolled; 17 subjects were treated; 1 subject was not eligible. The completed subjects withdrew from last study treatment due to progressive disease.

Arm type	Experimental
Investigational medicinal product name	Figitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Figitumumab 20 milligram/kilogram (mg/kg) intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year).

Investigational medicinal product name	Pegvisomant
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year).

Arm title	Figitumumab 20mg/kg + Pegvisomant 20 mg
------------------	---

Arm description:

Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Figitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Figitumumab 20 mg/kg intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year).

Investigational medicinal product name	Pegvisomant
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year).

Number of subjects in period 1	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg
Started	17	6
Completed	3	0
Not completed	14	6
Termination by Sponsor	-	1
Consent withdrawn by subject	1	-
Death	7	1
Subject Enrolled in Hospice	1	-
Lost to follow-up	1	-
Disease Progression	4	4

Baseline characteristics

Reporting groups

Reporting group title	Figitumumab 20mg/kg + Pegvisomant 10 mg
-----------------------	---

Reporting group description:

Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days. 18 subjects were enrolled; 17 subjects were treated; 1 subject was not eligible. The completed subjects withdrew from last study treatment due to progressive disease.

Reporting group title	Figitumumab 20mg/kg + Pegvisomant 20 mg
-----------------------	---

Reporting group description:

Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Reporting group values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg	Total
Number of subjects	17	6	23
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	49.5	32.3	
standard deviation	± 17.4	± 9.8	-
Gender categorical Units: Subjects			
Female	8	5	13
Male	9	1	10

End points

End points reporting groups

Reporting group title	Figitumumab 20mg/kg + Pegvisomant 10 mg
Reporting group description: Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days. 18 subjects were enrolled; 17 subjects were treated; 1 subject was not eligible. The completed subjects withdrew from last study treatment due to progressive disease.	
Reporting group title	Figitumumab 20mg/kg + Pegvisomant 20 mg
Reporting group description: Figitumumab administered on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant administered subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily, up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.	

Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) ^[1]
End point description: Counts of subjects who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. AEs were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 (Grade [Gr] 1 = Mild, Gr 2 = Moderate, Gr 3=Severe, Gr 4 = Life-threatening or disabling, Gr 5 = Death). Relatedness to [study drug] was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category. Safety analysis set: all enrolled subjects who received at least 1 dose of either of the study medications.	
End point type	Primary
End point timeframe: From Screening to the follow-up visit (90 days after last dose of figitumumab)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	6		
Units: Subjects				
Number of Subjects with AEs	17	6		
Number of subjects with SAEs	9	4		
Number of subjects with Gr 3 or Gr 4 AEs	12	4		
Number of subjects with Gr 5 AEs	7	1		

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Dose Limiting Toxicities (DLT)

End point title	Number of Subjects With Dose Limiting Toxicities (DLT) ^[2]
-----------------	---

End point description:

DLT was defined as any of the following events occurring during DLT period and considered related to study medication: Gr 4 neutropenia lasting more than or equal to (\geq) 7 days, febrile neutropenia (Gr 3 or 4 neutropenia, fever ≥ 38.5 degrees Celsius ($^{\circ}\text{C}$), lasting over 24 hours), neutropenic infection (Gr ≥ 3 neutropenia infection); Gr 3 or 4 thrombocytopenia associated with bleeding or Gr 4 thrombocytopenia ≥ 7 days; Gr 3 or 4 lymphopenia accompanied by an opportunistic infection; other non-hematologic Gr 4 toxicities or symptomatic Gr 3 toxicities that require medical intervention and 14 days to resolve. Safety analysis set: all enrolled subjects who received at least 1 dose of either of the study medications. N= Number of subjects remained on treatment throughout the required DLT period and included as analyzed for DLT based on the defined DLT evaluability specifications were analyzed for this endpoint.

End point type	Primary
----------------	---------

End point timeframe:

From Cycle 2, Day 1 to Cycle 3, Day 8; from Cycle 1, Day 15 to end of Cycle 2

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported for this endpoint.

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: Subjects	1	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Circulating Insulin-like Growth Factor (IGF-1) Levels

End point title	Serum Circulating Insulin-like Growth Factor (IGF-1) Levels
-----------------	---

End point description:

The effect of the combined therapy with figitumumab and pegvisomant on circulating concentrations of total IGF-1 was assessed. Biomarker analysis set: all enrolled subjects who had at least 1 baseline or on-study sample submitted. N=number of participants who were evaluable for IGF-1 Levels at prespecified time points. For this endpoint "99999" signifies not available (NA). For Figitumumab 20 mg/kg + Pegvisomant 10 mg reporting group in cycle 7 Standard deviation (SD) was not calculated as only 1 out of 17 subjects were evaluable ; In Figitumumab 20 mg/kg + Pegvisomant 10 mg reporting group for Cycle 08 to Cycle 27, Mean and SD were not calculated as the data was not analyzed since no subjects were evaluable; for Figitumumab 20mg/kg + Pegvisomant 20 mg reporting groupMean and SD were not calculated as only 1 out of 6 subjects were evaluable.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 and 15 of Cycle 1 (Baseline); Day 1 of subsequent cycles starting from Cycle 2 to Cycle 27; end of treatment (21 days after last dose of figitumumab); follow-up visit (90 days after last dose of figitumumab)

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	6		
Units: nanogram/milliliter (ng/mL)				
arithmetic mean (standard deviation)				
Baseline/Cycle 1 (n = 16, 6)	150.18 (± 77.06)	189.17 (± 59.79)		
Cycle 2 (n = 12, 6)	725.72 (± 497.12)	498.5 (± 218.28)		
Cycle 3 (n = 6, 5)	474.53 (± 418.39)	247.4 (± 147.41)		
Cycle 4 (n = 5, 3)	542.09 (± 510.84)	124.67 (± 83.94)		
Cycle 5 (n = 3, 4)	990.4 (± 542.21)	248.25 (± 127.43)		
Cycle 6 (n = 2, 2)	1369.5 (± 161.93)	122.5 (± 137.89)		
Cycle 7 (n = 1, 2)	1594 (± 99999)	272.5 (± 105.36)		
Cycle 8 (n = 0, 2)	99999 (± 99999)	501 (± 94.75)		
Cycle 9 (n = 0, 2)	99999 (± 99999)	331 (± 229.1)		
Cycle 10 (n = 0, 2)	99999 (± 99999)	412.5 (± 185.97)		
Cycle 11 (n = 0, 2)	99999 (± 99999)	426.5 (± 119.5)		
Cycle 12 (n = 0, 2)	99999 (± 99999)	375.5 (± 350.02)		
Cycle 13 (n = 0, 2)	99999 (± 99999)	457.5 (± 36.06)		
Cycle 14 (n = 0, 2)	99999 (± 99999)	420 (± 45.25)		
Cycle 15 (n = 0, 2)	99999 (± 99999)	444.5 (± 47.38)		
Cycle 16 (n = 0, 2)	99999 (± 99999)	443.5 (± 23.33)		
Cycle 17 (n = 0, 2)	99999 (± 99999)	426 (± 4.24)		
Cycle 18 (n = 0, 2)	99999 (± 99999)	570.5 (± 487.2)		
Cycle 19 (n = 0, 1)	99999 (± 99999)	537 (± 99999)		
Cycle 20 (n = 0, 2)	99999 (± 99999)	458.5 (± 239.71)		
Cycle 21 (n = 0, 2)	99999 (± 99999)	437 (± 21.21)		
Cycle 22 (n = 0, 1)	99999 (± 99999)	401 (± 99999)		
Cycle 23 (n = 0, 1)	99999 (± 99999)	481 (± 99999)		
Cycle 24 (n = 0, 1)	99999 (± 99999)	361 (± 99999)		

Cycle 25 (n = 0, 1)	99999 (± 99999)	424 (± 99999)		
Cycle 26 (n = 0, 1)	99999 (± 99999)	366 (± 99999)		
Cycle 27 (n = 0, 0)	99999 (± 99999)	99999 (± 99999)		
Follow-Up (n = 2, 1)	791.5 (± 813.88)	1285 (± 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Cycle 1: Maximum Observed Plasma Concentration (Cmax) of Figitumumab

End point title	Cycle 1: Maximum Observed Plasma Concentration (Cmax) of Figitumumab
-----------------	--

End point description:

Pharmacokinetic (PK) samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Day 1 (within 2 hours before figitumumab infusion), Day 2 (1 hour post figitumumab infusion), Day 8 and Day 15

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[3]	0 ^[4]		
Units: ng/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[3] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[4] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax) of Figitumumab

End point title	Maximum Observed Plasma Concentration (Cmax) of Figitumumab
-----------------	---

End point description:

PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 2: Day 1 (within 2 hours before and 1 hour after figitumumab infusion); Cycle 3 to Cycle 17: Day 1 (within 2 hours before figitumumab infusion); end of treatment; 90-day follow-up visit

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[5]	0 ^[6]		
Units: ng/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[5] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[6] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Cycle 1: Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab

End point title	Cycle 1: Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab
-----------------	--

End point description:

PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 1: Day 1 (within 2 hours before figitumumab infusion), Day 2 (1 hour post figitumumab infusion), Day 8 and Day 15

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[7]	0 ^[8]		
Units: ng/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[7] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[8] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab

End point title	Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab
-----------------	---

End point description:

Plasma Concentration at the Last Quantifiable Time Point (Clast) of Figitumumab from Cycle 2 to the end of treatment. PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 2: Day 1 (within 2 hours before and 1 hour after figitumumab infusion); Cycle 3 to Cycle 17: Day 1 (within 2 hours before figitumumab infusion); end of treatment; 90-day follow-up visit.

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[9]	0 ^[10]		
Units: ng/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[9] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[10] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Cycle 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab

End point title	Cycle 1: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab
-----------------	--

End point description:

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) of figitumumab in cycle 1. PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1, 2, 8 and 15 of Cycle 1; Day 1 of subsequent cycle starting from Cycle 2 (up to Cycle 17); end of treatment (21 days after last dose of figitumumab); follow-up visit (90 days after last dose of figitumumab).

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[11]	0 ^[12]		
Units: nanogram*hours/milliliter (ng*hr/mL)				
arithmetic mean (standard deviation)	()	()		

Notes:

[11] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[12] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab

End point title	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Figitumumab
-----------------	---

End point description:

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) of figitumumab after Cycle 1. PK samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycle 2: Day 1 (within 2 hours before and 1 hour after figitumumab infusion); Cycle 3 to Cycle 17: Day 1 (within 2 hours before figitumumab infusion); end of treatment; 90-day follow-up visit.

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[13]	0 ^[14]		
Units: ng*hr/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[13] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[14] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Trough Concentrations (AUCtrough)

End point title	Area Under the Trough Concentrations (AUCtrough)
-----------------	--

End point description:

The trough concentration-time profile (AUCtrough) of pegvisomant was to be analyzed by noncompartmental methods. PK samples were not analyzed as the study was terminated prematurely

due to lack of operational feasibility and the halt of figitumumab development.

End point type	Secondary
End point timeframe:	
Cycle 1: Day 15 (within 2 hours before loading dose), Day 16 (within 2 hours pre-SC dose); Cycle 2: Days 1, 8 and 15 (within 2 hours pre-SC dose); Cycle 3 up to Cycle 17: Day 1 (within 2 hours pre-SC dose); end of treatment; 90-day follow-up visit.	

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[15]	0 ^[16]		
Units: ng*hr/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[15] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[16] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change in Glucose Levels Between Fasting and Post Glucose Load

End point title	Mean Change in Glucose Levels Between Fasting and Post Glucose Load
-----------------	---

End point description:

The effect of combining figitumumab with pegvisomant was analyzed to assess whether pegvisomant reverses figitumumab-induced glucose intolerance at various pegvisomant dose levels. The change in glucose load was assessed by Glucose Tolerance Testing (GTT) at baseline (fasting), during Cycle 1 following administration of figitumumab alone (post load), and near the end of Cycle 2 (post load) following combined therapy with figitumumab and pegvisomant. Glucose tolerance set: All enrolled subjects who started treatment and who had at least one baseline or on-study sample submitted. n=number of subjects with analyzable data for this outcome measure at specific time point.

End point type	Secondary
End point timeframe:	
Screening; Day 8 of Cycle 1; Day 15 of Cycle 2	

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	6		
Units: milligram/deciliter (mg/dL)				
arithmetic mean (standard deviation)				
Screening (n = 17, 6)	30.35 (± 34.02)	4.67 (± 17.6)		
Cycle 1 Day 8 (n = 15, 5)	37.68 (± 30.95)	15.4 (± 32.04)		

Cycle 2 Day 15 (n = 4, 5)	55.15 (± 49.35)	13.4 (± 28.35)		
---------------------------	-----------------	----------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab

End point title	Percentage of Subjects Reporting Positive Anti-Drug Antibodies (ADA) Response for Figitumumab
End point description: Percentage of subjects with positive total or neutralizing ADA for figitumumab. ADA samples were not analyzed as the study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.	
End point type	Secondary
End point timeframe: Day 1 of Cycles 1 and 4; end of treatment (21 days after last dose of figitumumab); follow-up visit (90 days after last dose of figitumumab)	

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[17]	0 ^[18]		
Units: percentage of subjects				

Notes:

[17] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

[18] - Study was terminated due to lack of operational feasibility and the halt of figitumumab development.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects With Objective Response

End point title	Number of subjects With Objective Response
End point description: Number of subjects with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as ≥30% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST version 1.1. Confirmed responses are those that persist on repeat imaging study ≥4 weeks after initial documentation of response. Response-evaluable set: All subjects who started Cycle 1 with an adequate baseline tumor assessment and at least 1 follow up tumor assessment were analysed for this outcome measure.	
End point type	Secondary
End point timeframe: From Screening, odd numbered cycles (pre- dose, Cycle 3, 5, 7 etc.) up to Cycle 27 or end of treatment	

End point values	Figitumumab 20mg/kg + Pegvisomant 10 mg	Figitumumab 20mg/kg + Pegvisomant 20 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	17	6		
Units: subjects	0	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AE and SAE were reported from first dose of the study treatment up to 90 -150 days after last dose of study treatment, death were reported from first dose of study treatment up to 28 days after last dose of study treatment

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

Reporting groups

Reporting group title	Figitumumab 20 mg/kg + Pegvisomant 10 mg
-----------------------	--

Reporting group description:

Figitumumab 20 mg/kg intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles, up to a maximum of 17 cycles (corresponding to 1 year). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 10 mg subcutaneously once daily up to a maximum of 17 cycles (corresponding to 1 year). Each cycle was of 21 days.

Reporting group title	Figitumumab 20 mg/kg + Pegvisomant 20 mg
-----------------------	--

Reporting group description:

Figitumumab 20 mg/kg intravenously over 1 to 2.5 hours on Day 1 and 2 of Cycle 1 and on Day 1 of subsequent cycles (up to total duration of 27 cycles). Pegvisomant 40 mg subcutaneously on Day 15 of Cycle 1 or Day 1 of Cycle 2 and thereafter pegvisomant 20 mg subcutaneously once daily up to total duration of 27 cycles. Each cycle was of 21 days.

Serious adverse events	Figitumumab 20 mg/kg + Pegvisomant 10 mg	Figitumumab 20 mg/kg + Pegvisomant 20 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 17 (52.94%)	4 / 6 (66.67%)	
number of deaths (all causes)	2	0	
number of deaths resulting from adverse events	1	0	
Investigations			
Blood uric acid increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
C-reactive protein increased			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Nervous system disorders			
Cauda equina syndrome			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Medical device complication			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fatigue			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disease progression			
subjects affected / exposed	4 / 17 (23.53%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 5	0 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pain			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pyrexia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pelvic infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Figitumumab 20 mg/kg + Pegvisomant 10 mg	Figitumumab 20 mg/kg + Pegvisomant 20 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 17 (100.00%)	6 / 6 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Vaginal neoplasm			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Haematoma			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Pelvic venous thrombosis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Chest pain			
subjects affected / exposed	2 / 17 (11.76%)	2 / 6 (33.33%)	
occurrences (all)	4	6	
Disease progression			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Exercise tolerance decreased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	13 / 17 (76.47%)	4 / 6 (66.67%)	
occurrences (all)	18	8	

General physical health deterioration		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Chills		
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)
occurrences (all)	2	0
Injection site reaction		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Medical device pain		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Mucosal inflammation		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Necrosis		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Oedema peripheral		
subjects affected / exposed	2 / 17 (11.76%)	1 / 6 (16.67%)
occurrences (all)	2	2
Injection site induration		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Thirst		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Pyrexia		
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)
occurrences (all)	1	1
Peripheral swelling		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Pain		
subjects affected / exposed	2 / 17 (11.76%)	1 / 6 (16.67%)
occurrences (all)	2	2

Immune system disorders Contrast media allergy subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1	
Reproductive system and breast disorders Vaginal ulceration subjects affected / exposed occurrences (all) Atrophic vulvovaginitis subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1 0 / 17 (0.00%) 0	0 / 6 (0.00%) 0 1 / 6 (16.67%) 2	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Hiccups subjects affected / exposed occurrences (all) Dyspnoea exertional subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all) Dysphonia subjects affected / exposed occurrences (all) Pleural effusion subjects affected / exposed occurrences (all) Pulmonary congestion subjects affected / exposed occurrences (all)	4 / 17 (23.53%) 7 1 / 17 (5.88%) 2 2 / 17 (11.76%) 3 0 / 17 (0.00%) 0 3 / 17 (17.65%) 4 1 / 17 (5.88%) 2 1 / 17 (5.88%) 1 1 / 17 (5.88%) 1	1 / 6 (16.67%) 1 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0 1 / 6 (16.67%) 1 1 / 6 (16.67%) 3 1 / 6 (16.67%) 2 0 / 6 (0.00%) 0 0 / 6 (0.00%) 0	

Pulmonary embolism subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0	
Wheezing subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 2	0 / 6 (0.00%) 0	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0	
Confusional state subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0	
Depression subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 2	0 / 6 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 2	0 / 6 (0.00%) 0	
Investigations Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1	
C-reactive protein increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 6 (16.67%) 3	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 6 (16.67%) 1	
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 6 (0.00%) 0	
Blood creatinine increased			

subjects affected / exposed	3 / 17 (17.65%)	2 / 6 (33.33%)	
occurrences (all)	5	2	
Blood uric acid increased			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	10	0	
Blood albumin decreased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	3	0	
Haemoglobin decreased			
subjects affected / exposed	3 / 17 (17.65%)	1 / 6 (16.67%)	
occurrences (all)	4	3	
Insulin-like growth factor increased			
subjects affected / exposed	0 / 17 (0.00%)	2 / 6 (33.33%)	
occurrences (all)	0	3	
International normalised ratio increased			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Neutrophil count decreased			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Weight decreased			
subjects affected / exposed	3 / 17 (17.65%)	3 / 6 (50.00%)	
occurrences (all)	6	5	
Platelet count decreased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Weight increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	5	
Thermal burn			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Procedural pain			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Fall			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	5	0	
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Nervous system disorders			
Dyskinesia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Dysgeusia			
subjects affected / exposed	3 / 17 (17.65%)	0 / 6 (0.00%)	
occurrences (all)	6	0	
Facial nerve disorder			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Convulsion			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Dizziness			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Hemiparesis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Headache			

subjects affected / exposed	2 / 17 (11.76%)	2 / 6 (33.33%)	
occurrences (all)	7	3	
Intracranial pressure increased			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Paraesthesia mucosal			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Paraesthesia			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Sensory disturbance			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Somnolence			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	2	2	
Spinal cord compression			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Anaemia			
subjects affected / exposed	1 / 17 (5.88%)	2 / 6 (33.33%)	
occurrences (all)	2	2	
Thrombocytopenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Neutropenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Ear discomfort			

subjects affected / exposed	1 / 17 (5.88%)	2 / 6 (33.33%)	
occurrences (all)	2	2	
Hearing impaired			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Sudden hearing loss			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Ocular hyperaemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	3	0	
Abdominal discomfort			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Abdominal distension			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	2	1	
Dry mouth			
subjects affected / exposed	3 / 17 (17.65%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Diarrhoea			
subjects affected / exposed	7 / 17 (41.18%)	4 / 6 (66.67%)	
occurrences (all)	7	5	
Abdominal pain upper			
subjects affected / exposed	0 / 17 (0.00%)	2 / 6 (33.33%)	
occurrences (all)	0	3	
Abdominal pain lower			

subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Constipation		
subjects affected / exposed	5 / 17 (29.41%)	2 / 6 (33.33%)
occurrences (all)	6	5
Flatulence		
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)
occurrences (all)	2	0
Gastric ulcer		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Eructation		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	2	0
Erosive oesophagitis		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	1	0
Dysphagia		
subjects affected / exposed	0 / 17 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	2
Dyspepsia		
subjects affected / exposed	2 / 17 (11.76%)	3 / 6 (50.00%)
occurrences (all)	2	9
Gastrooesophageal reflux disease		
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)
occurrences (all)	2	0
Gastritis		
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)
occurrences (all)	1	1
Hiatus hernia		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Impaired gastric emptying		
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	1
Nausea		

subjects affected / exposed	9 / 17 (52.94%)	2 / 6 (33.33%)	
occurrences (all)	13	3	
Proctalgia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Rectal haemorrhage			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Vomiting			
subjects affected / exposed	4 / 17 (23.53%)	1 / 6 (16.67%)	
occurrences (all)	8	1	
Stomatitis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Hepatobiliary disorders			
Cholangitis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Alopecia			
subjects affected / exposed	2 / 17 (11.76%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Nail disorder			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Ecchymosis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Dry skin			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Pruritus			

subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Skin disorder			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Psoriasis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Pruritus generalised			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Urticaria			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Pollakiuria			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Musculoskeletal and connective tissue disorders			
Bone swelling			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Back pain			
subjects affected / exposed	2 / 17 (11.76%)	3 / 6 (50.00%)	
occurrences (all)	2	3	
Joint swelling			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Flank pain			

subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Muscle spasms			
subjects affected / exposed	5 / 17 (29.41%)	3 / 6 (50.00%)	
occurrences (all)	6	5	
Muscular weakness			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	2	0	
Musculoskeletal chest pain			
subjects affected / exposed	2 / 17 (11.76%)	1 / 6 (16.67%)	
occurrences (all)	6	1	
Myalgia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	2 / 17 (11.76%)	1 / 6 (16.67%)	
occurrences (all)	2	3	
Spinal pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	5	0	
Infections and infestations			
Fungal infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Lung infection			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	2	4	
Nasopharyngitis			
subjects affected / exposed	1 / 17 (5.88%)	1 / 6 (16.67%)	
occurrences (all)	1	1	
Paronychia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	

Pelvic infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Urinary tract infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Upper respiratory tract infection			
subjects affected / exposed	2 / 17 (11.76%)	1 / 6 (16.67%)	
occurrences (all)	3	1	
Sinusitis			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Wound infection			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Rhinitis			
subjects affected / exposed	0 / 17 (0.00%)	2 / 6 (33.33%)	
occurrences (all)	0	7	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	5 / 17 (29.41%)	0 / 6 (0.00%)	
occurrences (all)	7	0	
Dehydration			
subjects affected / exposed	4 / 17 (23.53%)	0 / 6 (0.00%)	
occurrences (all)	4	0	
Decreased appetite			
subjects affected / exposed	9 / 17 (52.94%)	2 / 6 (33.33%)	
occurrences (all)	11	3	
Hyponatraemia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 6 (0.00%)	
occurrences (all)	1	0	
Hypocalcaemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	2	
Hyperkalaemia			

subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Hypermagnesaemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	
Hypernatraemia			
subjects affected / exposed	0 / 17 (0.00%)	1 / 6 (16.67%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 May 2010	1) Gamma-glutamyl transpeptidase (GGT) assessment was added to the Safety Laboratory tests, in addition fasting glucose assessment was modified from 4 hours to 8 hours.
02 May 2011	Safety Laboratory parameters assessment was modified to be performed and reviewed prior to beginning of each new cycle of therapy.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated prematurely due to lack of operational feasibility and the halt of figitumumab development.

Notes: